ERBB2 and breast carcinoma: The goal of these clinical trials is to develop an effective and safe targeted therapy-based regimen which will overcome multiple drug resistance mechanisms typical of HR+/HER2+ breast cancer, resulting in the improved response to neoadjuvant treatment in early disease, as well as prolonged PFS and improved quality of life in metastatic settings.